688062 邁威生物
按盤價 
59.970 +0.800 (+1.352%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 101,165 | -12.43% | 199,782 | 127,836 | 27,728 | 16,226 | |
| 減：營業總成本 | 671,701 | 18.48% | 1,259,798 | 1,175,895 | 993,419 | 819,034 | |
| 其中:營業成本 | 21,548 | 249.11% | 28,952 | 1,370 | 71 | 3,079 | |
| 財務費用 | 36,265 | 194.15% | 36,726 | (33,411) | (34,764) | 3,478 | |
| 資產減值損失 | (7,690) | 4.55% | (5,527) | (9,488) | (1,940) | (2,144) | |
| 公允價值變動收益 | 18 | -89.92% | 493 | (3,043) | 1,082 | (230) | |
| 投資收益 | (2,866) | 64.97% | (4,219) | (1,649) | 714 | 4,084 | |
| 其中：對聯營企業和合營企業的投資收益 | (3,150) | -7.57% | (7,058) | (2,594) | (476) | (176) | |
| 營業利潤 | (552,443) | 24.62% | (1,043,480) | (1,052,579) | (958,139) | (772,696) | |
| 利潤總額 | (552,176) | 24.27% | (1,047,471) | (1,055,288) | (958,126) | (772,700) | |
| 減：所得稅費用 | 54 | -97.15% | (907) | 3,524 | -- | -- | |
| 淨利潤 | (552,230) | 23.75% | (1,046,565) | (1,058,811) | (958,126) | (772,700) | |
| 減：非控股權益 | (911) | -27.87% | (2,645) | (5,379) | (2,891) | (3,113) | |
| 股東淨利潤 | (551,319) | 23.90% | (1,043,919) | (1,053,433) | (955,235) | (769,587) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -1.380 | 24.32% | -2.610 | -2.640 | -2.440 | -2.570 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 2.047 | -62.27% | 3.926 | 6.466 | 8.798 | 3.373 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 03/09/2025 16:06 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
